作者: Christine B. Ambrosone , Chi-Chen Hong , Pamela J. Goodwin
DOI: 10.1007/978-3-319-16366-6_10
关键词:
摘要: Among women with breast cancer, there is wide variability in outcomes, both treatment-related toxicities and disease-free survival (DFS). Primary predictors of DFS are those related to the extent disease tumor characteristics, associated not only aggressiveness, but also responsiveness targeted therapies. Inherited germline variation may play a role cancer treatment have been studies targeting drug metabolism other candidate pathways as well genome-wide association (GWAS), which take more agnostic approach interrogate hundreds thousands single nucleotide polymorphisms (SNPs) determine that modify response treatment. While this field pharmacogenetics pharmacogenomics has held exciting promise for personalized medicine, results consistent, or effects profound, first hoped. An emerging prognosis epigenetics, regulates DNA expression can be influenced by numerous biologic processes environmental exposures. Although young, research likely holds understanding epigenetic mechanisms driving potential these factors through drugs approaches. Finally, circulating markers blood reflect some lifestyle relation particularly Vitamin D. In chapter, we highlight advances areas noted above, comment on impact interpretation from observational studies. We discuss future directions, avenues necessary move forward.